News

Video

Dr Husain on Developments in ALK+ NSCLC

Author(s):

Hatim Husain, MD
Conference|International Lung Cancer Congress

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Hatim Husain, MD, medical oncologist and assistant professor of medicine at Moores Cancer Center of the University of California, San Diego, discusses developments in ALK-positive non–small cell lung cancer.

Related Videos
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Related Content
Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Mansoor Raza Mirza, MD
June 7th 2024

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Charlene Mantia, MD, of Dana-Farber Cancer Institute
June 6th 2024

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

Roger Li, MD
June 6th 2024

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab